These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

209 related items for PubMed ID: 25354998

  • 1. Rationale and design of the Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis in Dilated Cardiomyopathy (the POSEIDON-DCM study): a phase I/II, randomized pilot study of the comparative safety and efficacy of transendocardial injection of autologous mesenchymal stem cell vs. allogeneic mesenchymal stem cells in patients with non-ischemic dilated cardiomyopathy.
    Mushtaq M, DiFede DL, Golpanian S, Khan A, Gomes SA, Mendizabal A, Heldman AW, Hare JM.
    J Cardiovasc Transl Res; 2014 Dec; 7(9):769-80. PubMed ID: 25354998
    [Abstract] [Full Text] [Related]

  • 2. Randomized Comparison of Allogeneic Versus Autologous Mesenchymal Stem Cells for Nonischemic Dilated Cardiomyopathy: POSEIDON-DCM Trial.
    Hare JM, DiFede DL, Rieger AC, Florea V, Landin AM, El-Khorazaty J, Khan A, Mushtaq M, Lowery MH, Byrnes JJ, Hendel RC, Cohen MG, Alfonso CE, Valasaki K, Pujol MV, Golpanian S, Ghersin E, Fishman JE, Pattany P, Gomes SA, Delgado C, Miki R, Abuzeid F, Vidro-Casiano M, Premer C, Medina A, Porras V, Hatzistergos KE, Anderson E, Mendizabal A, Mitrani R, Heldman AW.
    J Am Coll Cardiol; 2017 Feb 07; 69(5):526-537. PubMed ID: 27856208
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Comparison of allogeneic vs autologous bone marrow–derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial.
    Hare JM, Fishman JE, Gerstenblith G, DiFede Velazquez DL, Zambrano JP, Suncion VY, Tracy M, Ghersin E, Johnston PV, Brinker JA, Breton E, Davis-Sproul J, Schulman IH, Byrnes J, Mendizabal AM, Lowery MH, Rouy D, Altman P, Wong Po Foo C, Ruiz P, Amador A, Da Silva J, McNiece IK, Heldman AW, George R, Lardo A.
    JAMA; 2012 Dec 12; 308(22):2369-79. PubMed ID: 23117550
    [Abstract] [Full Text] [Related]

  • 5. Rationale and design of the Transendocardial Injection of Autologous Human Cells (bone marrow or mesenchymal) in Chronic Ischemic Left Ventricular Dysfunction and Heart Failure Secondary to Myocardial Infarction (TAC-HFT) trial: A randomized, double-blind, placebo-controlled study of safety and efficacy.
    Trachtenberg B, Velazquez DL, Williams AR, McNiece I, Fishman J, Nguyen K, Rouy D, Altman P, Schwarz R, Mendizabal A, Oskouei B, Byrnes J, Soto V, Tracy M, Zambrano JP, Heldman AW, Hare JM.
    Am Heart J; 2011 Mar 12; 161(3):487-93. PubMed ID: 21392602
    [Abstract] [Full Text] [Related]

  • 6. The Effect of Transendocardial Stem Cell Injection on Erectile Function in Men With Cardiomyopathy: Results From the TRIDENT, POSEIDON, and TAC-HFT Trials.
    Ory J, Saltzman RG, Blachman-Braun R, Dadoun S, DiFede DL, Premer C, Hurwitz B, Hare JM, Ramasamy R.
    J Sex Med; 2020 Apr 12; 17(4):695-701. PubMed ID: 32059936
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Does transendocardial injection of mesenchymal stem cells improve myocardial function locally or globally?: An analysis from the Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis (POSEIDON) randomized trial.
    Suncion VY, Ghersin E, Fishman JE, Zambrano JP, Karantalis V, Mandel N, Nelson KH, Gerstenblith G, DiFede Velazquez DL, Breton E, Sitammagari K, Schulman IH, Taldone SN, Williams AR, Sanina C, Johnston PV, Brinker J, Altman P, Mushtaq M, Trachtenberg B, Mendizabal AM, Tracy M, Da Silva J, McNiece IK, Lardo AC, George RT, Hare JM, Heldman AW.
    Circ Res; 2014 Apr 11; 114(8):1292-301. PubMed ID: 24449819
    [Abstract] [Full Text] [Related]

  • 9. Transendocardial mesenchymal stem cells and mononuclear bone marrow cells for ischemic cardiomyopathy: the TAC-HFT randomized trial.
    Heldman AW, DiFede DL, Fishman JE, Zambrano JP, Trachtenberg BH, Karantalis V, Mushtaq M, Williams AR, Suncion VY, McNiece IK, Ghersin E, Soto V, Lopera G, Miki R, Willens H, Hendel R, Mitrani R, Pattany P, Feigenbaum G, Oskouei B, Byrnes J, Lowery MH, Sierra J, Pujol MV, Delgado C, Gonzalez PJ, Rodriguez JE, Bagno LL, Rouy D, Altman P, Foo CW, da Silva J, Anderson E, Schwarz R, Mendizabal A, Hare JM.
    JAMA; 2014 Jan 01; 311(1):62-73. PubMed ID: 24247587
    [Abstract] [Full Text] [Related]

  • 10. Effect of aging on human mesenchymal stem cell therapy in ischemic cardiomyopathy patients.
    Golpanian S, El-Khorazaty J, Mendizabal A, DiFede DL, Suncion VY, Karantalis V, Fishman JE, Ghersin E, Balkan W, Hare JM.
    J Am Coll Cardiol; 2015 Jan 20; 65(2):125-32. PubMed ID: 25593053
    [Abstract] [Full Text] [Related]

  • 11. [A prospective, randomized, controlled trial of autologous mesenchymal stem cells transplantation for dilated cardiomyopathy].
    Wang JA, Xie XJ, He H, Sun Y, Jiang J, Luo RH, Fan YQ, Dong L.
    Zhonghua Xin Xue Guan Bing Za Zhi; 2006 Feb 20; 34(2):107-10. PubMed ID: 16626573
    [Abstract] [Full Text] [Related]

  • 12. The ixCELL-DCM Trial: Rationale and Design.
    Henry TD, Schaer GL, DeMaria A, Recker D, Remmers AE, Goodrich J, Patel AN.
    Cell Transplant; 2016 Feb 20; 25(9):1689-1699. PubMed ID: 27009022
    [Abstract] [Full Text] [Related]

  • 13. Intramyocardial and intracoronary autologous bone marrow-derived mesenchymal stromal cell treatment in chronic severe dilated cardiomyopathy.
    Chin SP, Poey AC, Wong CY, Chang SK, Tan CS, Ng MT, Chew KH, Lam KH, Cheong SK.
    Cytotherapy; 2011 Aug 20; 13(7):814-21. PubMed ID: 21526902
    [Abstract] [Full Text] [Related]

  • 14. Safety and efficacy of ixmyelocel-T: an expanded, autologous multi-cellular therapy, in dilated cardiomyopathy.
    Henry TD, Traverse JH, Hammon BL, East CA, Bruckner B, Remmers AE, Recker D, Bull DA, Patel AN.
    Circ Res; 2014 Sep 26; 115(8):730-7. PubMed ID: 25142002
    [Abstract] [Full Text] [Related]

  • 15. Study design and rationale for ELPIS: A phase I/IIb randomized pilot study of allogeneic human mesenchymal stem cell injection in patients with hypoplastic left heart syndrome.
    Kaushal S, Wehman B, Pietris N, Naughton C, Bentzen SM, Bigham G, Mishra R, Sharma S, Vricella L, Everett AD, Deatrick KB, Huang S, Mehta H, Ravekes WA, Hibino N, Difede DL, Khan A, Hare JM.
    Am Heart J; 2017 Oct 26; 192():48-56. PubMed ID: 28938963
    [Abstract] [Full Text] [Related]

  • 16. The impact of patient sex on the response to intramyocardial mesenchymal stem cell administration in patients with non-ischaemic dilated cardiomyopathy.
    Florea V, Rieger AC, Natsumeda M, Tompkins BA, Banerjee MN, Schulman IH, Premer C, Khan A, Valasaki K, Heidecker B, Mantero A, Balkan W, Mitrani RD, Hare JM.
    Cardiovasc Res; 2020 Nov 01; 116(13):2131-2141. PubMed ID: 32053144
    [Abstract] [Full Text] [Related]

  • 17. Intramyocardial transplantation of mesenchymal stromal cells for chronic myocardial ischemia and impaired left ventricular function: Results of the MESAMI 1 pilot trial.
    Guijarro D, Lebrin M, Lairez O, Bourin P, Piriou N, Pozzo J, Lande G, Berry M, Le Tourneau T, Cussac D, Sensebe L, Gross F, Lamirault G, Huynh A, Manrique A, Ruidavet JB, Elbaz M, Trochu JN, Parini A, Kramer S, Galinier M, Lemarchand P, Roncalli J.
    Int J Cardiol; 2016 Apr 15; 209():258-65. PubMed ID: 26901787
    [Abstract] [Full Text] [Related]

  • 18. Dose Comparison Study of Allogeneic Mesenchymal Stem Cells in Patients With Ischemic Cardiomyopathy (The TRIDENT Study).
    Florea V, Rieger AC, DiFede DL, El-Khorazaty J, Natsumeda M, Banerjee MN, Tompkins BA, Khan A, Schulman IH, Landin AM, Mushtaq M, Golpanian S, Lowery MH, Byrnes JJ, Hendel RC, Cohen MG, Valasaki K, Pujol MV, Ghersin E, Miki R, Delgado C, Abuzeid F, Vidro-Casiano M, Saltzman RG, DaFonseca D, Caceres LV, Ramdas KN, Mendizabal A, Heldman AW, Mitrani RD, Hare JM.
    Circ Res; 2017 Nov 10; 121(11):1279-1290. PubMed ID: 28923793
    [Abstract] [Full Text] [Related]

  • 19. Genetic determinants of responsiveness to mesenchymal stem cell injections in non-ischemic dilated cardiomyopathy.
    Rieger AC, Myerburg RJ, Florea V, Tompkins BA, Natsumeda M, Premer C, Khan A, Schulman IH, Vidro-Casiano M, DiFede DL, Heldman AW, Mitrani R, Hare JM.
    EBioMedicine; 2019 Oct 10; 48():377-385. PubMed ID: 31648988
    [Abstract] [Full Text] [Related]

  • 20. Reparative effects of allogeneic mesenchymal precursor cells delivered transendocardially in experimental nonischemic cardiomyopathy.
    Psaltis PJ, Carbone A, Nelson AJ, Lau DH, Jantzen T, Manavis J, Williams K, Itescu S, Sanders P, Gronthos S, Zannettino AC, Worthley SG.
    JACC Cardiovasc Interv; 2010 Sep 10; 3(9):974-83. PubMed ID: 20850099
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.